OBJECTIVES: Interferon (INF)-free therapies for the treatment of hepatitis C virus (HCV) offer better viral clearance rates and safety profiles than older therapies but are priced higher. These therapies have also been shown to have favorable cost-effectiveness profiles compared with older therapies; however, the cost-effectiveness of INF-free regimens relative to each other is unclear. The objective of this study was to assess the cost-effectiveness of treating genotype 1 (GT1) HCV patients with AbbVie 3D (paritaprevir [developed by AbbVie and Enanta] /ritonavir/ombitasvir/dasabuvir) +/- ribavirin compared with Harvoni® (sofosbuvir/ledipasvir) in the United States. METHODS: A cost-effectiveness Markov model, based on previous HCV models, had 13 health states: 8 disease progression states (F0-F4, decompensated cirrhosis, hepatocellular carcinoma, and liver transplant), 3 sustained virologic response states, and 2 mortality states (liver-related and non-liver-related death). Transition rates were obtained from previous models. Adverse events, treatment-related disutility, and efficacy rates were based on phase 3 clinical trials. Baseline patient characteristics were derived from AbbVie 3D phase 3 clinical trials. Treatment durations were 24 weeks for GT1a experienced cirrhotic patients with AbbVie 3D and 8 weeks for 26% of GT1 treatment naïve patients with Harvoni. Direct medical costs were based on a systematic literature review and drug costs were based on December 2014 Red Book.  The model was run over a lifetime horizon, discounting at 3% annually.  Outcomes were measured in quality-adjusted life-years (QALYs). Probabilistic simulation analysis (PSA) was conducted by varying all parameters simultaneously.  RESULTS: AbbVie 3D resulted in discounted lifetime costs per patient of $99,753 and 16.20 QALYs. Harvoni resulted in lifetime costs of $108,430 and 16.18 QALYs. With lower costs (-$8,677) and higher QALYs (0.02), AbbVie 3D dominated Harvoni. AbbVie 3D was superior in 98.4% of PSA simulations when QALYs were valued at $100,000 each. CONCLUSIONS: With higher QALYs and lower costs, AbbVie 3D dominated Harvoni in GT1-HCV-infected patients.